Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis

Haematologica. 2019 May;104(5):e211-e214. doi: 10.3324/haematol.2018.205229. Epub 2018 Nov 15.

¹ Department of Haematology, Plymouth University Medical School, UK simon.rule@nhs.net.
² Department of Medicine III, Klinikum der Universität München, LMU, Germany.
³ Department of Hematology & Oncology, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA.
⁴ Department of Hematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg-University, Mainz, Germany.
⁵ Centre for Haemato-Oncology, Barts Cancer Institute, London, UK.
⁶ Department of Medicine, Washington University, St. Louis, MO, USA.
⁷ Hematology Department, Hospital Universitario Infanta Leonor, Universidad Complutense, Madrid, Spain.
⁸ Janssen Research & Development, Raritan, NJ, USA.
⁹ Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

No abstract available

Publication types